Research and Markets has announced the addition of the "Global Cancer Immunotherapies Market to 2022" report to their offering.

The market size for cancer immunotherapies is expected to grow more than fourfold from $16.9 billion in 2015 to $75.8 billion by 2022, representing a rapid compound annual growth rate (CAGR) of 23.9%.

Over the past few decades cancer immunotherapies have developed into important therapeutic options for some types of cancer. Some of these therapies generally enhance the activity of the body's immune system, while others drive the immune system to target specific cancer cells.

Overall, there are 2,037 products in active development in the cancer immunotherapy pipeline. This makes it a notable portion of the entire oncology pipeline, and reflects the strong interest in this class of therapy in product development. This is due to growing clinical rationale behind developing such therapies, and the willingness of drug developers to invest in novel therapeutics, which will offer significant product differentiation from market competitors.

The leading indications in terms of cancer immunotherapy product development are breast cancer, melanoma, non-small-cell lung cancer (NSCLC) and ovarian cancer, which are the focus of this report. This is based on the high level of activity in terms of cancer immunotherapy product development in these specific oncology indications, with the aforementioned indications ranking highest in this regard.

Key Topics Covered:

1 List of Tables & Figures

2 Introduction

3 Key Marketed Products

4 Pipeline Landscape Assessment

5 Multi-scenario Market Forecast to 2022

6 Company Analysis and Positioning

7 Strategic Consolidations

8 Appendix

For more information about this report visit http://www.researchandmarkets.com/research/nh27fh/global_cancer